Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to $4.9 million.

  • Fate Therapeutics' Share-based Compensation fell 5868.25% to $4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.5 million, marking a year-over-year decrease of 3186.3%. This contributed to the annual value of $41.5 million for FY2024, which is 451.69% down from last year.
  • Fate Therapeutics' Share-based Compensation amounted to $4.9 million in Q3 2025, which was down 5868.25% from $7.2 million recorded in Q2 2025.
  • Fate Therapeutics' 5-year Share-based Compensation high stood at $20.5 million for Q2 2022, and its period low was $4.9 million during Q3 2025.
  • Moreover, its 5-year median value for Share-based Compensation was $11.8 million (2024), whereas its average is $12.5 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 8770.43% in 2021, then tumbled by 5868.25% in 2025.
  • Fate Therapeutics' Share-based Compensation (Quarter) stood at $14.6 million in 2021, then skyrocketed by 32.88% to $19.4 million in 2022, then tumbled by 51.14% to $9.5 million in 2023, then decreased by 3.75% to $9.1 million in 2024, then plummeted by 46.7% to $4.9 million in 2025.
  • Its Share-based Compensation stands at $4.9 million for Q3 2025, versus $7.2 million for Q2 2025 and $7.4 million for Q1 2025.